Zoetis (ZTS) Stock Analysis: Why the Hold Rating? | 2-Minute Analysis

Key Concepts

Zoetis (ZTS): A pharmaceutical company focused on animal health.
Quant Rating: Seeking Alpha’s proprietary stock rating system.
Enterprise Value to EBITDA: A valuation metric comparing a company’s value to its earnings before interest, taxes, depreciation, and amortization.
PEG Ratio (Price/Earnings to Growth): A valuation metric used to determine the relative trade-off between the P/E ratio and a company’s expected growth rate.
Net Income Margin: A profitability ratio measuring the percentage of revenue that translates into profit.
Dividend Yield: The annual dividend payment as a percentage of the stock price.
Dividend Safety: An assessment of the sustainability of a company’s dividend payments.

Zoetis Incorporated (ZTS) – 2-Minute Stock Analysis

This analysis provides a rapid overview of Zoetis Incorporated (ZTS), a $54.92 billion market capitalization company operating within the healthcare sector, specifically the pharmaceuticals industry. The assessment utilizes the Seeking Alpha Quant rating system, analyst ratings, and Wall Street consensus.

Ratings Overview

The Seeking Alpha Quant system currently assigns a Hold rating to ZTS. Seeking Alpha analysts also maintain a Hold rating, aggregated from five analysts covering the stock in the last 90 days. In contrast, Wall Street analysts express a Buy rating, based on coverage from 20 analysts over the same period.

Valuation Analysis

Zoetis’ valuation receives a D- grade. The Enterprise Value to EBITDA ratio is 14.65, slightly above the sector median of 12.71, suggesting a relatively fair valuation based on this metric. However, the PEG Non-GAAP Forward ratio stands at 2.58, exceeding the sector average of 1.76. This higher PEG ratio indicates potential overvaluation when considering the company’s growth prospects.

Growth Performance

The company’s growth rate is also rated a D-. Year-over-year revenue growth is reported at 2.68%, falling below the sector median of 6.38%. This growth is also lower than Zoetis’ 5-year average revenue growth of 8.06%.

Profitability & Momentum

Zoetis demonstrates strong profitability, earning an A+ grade. Its Net Income Margin is 28.21%, significantly higher than the sector average of approximately 0.5%. However, the stock’s momentum is weak, receiving a D+ grade. The one-year price performance is down 25.07%, while the sector remains largely flat.

Earnings & Revenue Revisions

Recent revisions to earnings per share (EPS) and revenue estimates are negative. Over the last three months, there have been three upward revisions and 12 downward revisions for EPS, and one upward revision and 14 downward revisions for revenue. This trend, reflected in a D+ revisions grade, suggests declining analyst confidence in the company’s near-term performance.

Dividend Analysis

Zoetis is a dividend-paying stock with a current yield of 1.70%. The 5-year dividend growth rate is a robust 20.11%. The stock receives a Safety grade of A, a Growth grade of A+, a Yield grade of C, and a Consistency grade of B-. The company has consistently paid dividends for 12 years, and its strong cash flow from operations (reported at $2.92 billion) supports the sustainability of these payments.

Safety & Follow-Up

The company’s dividend safety is considered strong due to its substantial cash flow. Viewers are encouraged to follow Zoetis on Seeking Alpha for breaking news alerts.

Disclaimer

The analysis concludes with a standard disclaimer: past performance is not indicative of future results, and the content is for informational purposes only, not constituting personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker, or investment advisor.